X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (510) 510
Publication (79) 79
Book Review (7) 7
Book Chapter (4) 4
Dissertation (2) 2
Conference Proceeding (1) 1
Data Set (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (308) 308
immunotherapy (270) 270
anti-ctla-4 (268) 268
humans (231) 231
oncology (228) 228
ipilimumab (227) 227
melanoma (198) 198
cancer (177) 177
metastatic melanoma (160) 160
immunology (125) 125
antibodies, monoclonal - therapeutic use (106) 106
anti-ctla-4 antibody (99) 99
animals (95) 95
anti-pd-1 (93) 93
nivolumab (86) 86
female (82) 82
melanoma - drug therapy (82) 82
male (77) 77
antibodies, monoclonal - adverse effects (69) 69
anti-ctla-4 antibodies (68) 68
care and treatment (67) 67
blockade (66) 66
ctla-4 blockade (66) 66
middle aged (66) 66
adverse events (64) 64
ctla-4 antigen - immunology (63) 63
antineoplastic agents - therapeutic use (62) 62
regulatory t-cells (62) 62
ctla-4 (61) 61
lymphocytes (61) 61
metastasis (61) 61
t cells (60) 60
therapy (60) 60
tumors (60) 60
ctla-4 antigen - antagonists & inhibitors (59) 59
mice (58) 58
pembrolizumab (55) 55
aged (54) 54
antigens (52) 52
immune checkpoint (50) 50
chemotherapy (48) 48
advanced melanoma (47) 47
anti-ctla-4 therapy (47) 47
immunotherapy - methods (47) 47
melanoma - immunology (47) 47
cancer-immunotherapy (46) 46
medicine, research & experimental (46) 46
lymphocytes t (45) 45
antibodies (44) 44
open-label (44) 44
pd-1 (44) 44
immune checkpoint inhibitors (41) 41
treatment outcome (41) 41
monoclonal antibodies (40) 40
survival (40) 40
adult (39) 39
antineoplastic agents - adverse effects (39) 39
antitumor immunity (38) 38
article (38) 38
t-cells (37) 37
dendritic cells (36) 36
skin neoplasms - drug therapy (36) 36
analysis (35) 35
antibodies, monoclonal - administration & dosage (35) 35
cytotoxicity (35) 35
neoplasms - immunology (35) 35
research (35) 35
checkpoint inhibitors (34) 34
medicine & public health (34) 34
clinical trials (33) 33
melanoma - pathology (33) 33
cell line, tumor (32) 32
health aspects (32) 32
cancer therapies (31) 31
monoclonal-antibody (31) 31
safety (31) 31
antibodies, monoclonal - immunology (30) 30
antibody (30) 30
immune system (30) 30
lymphocyte-associated antigen-4 (30) 30
prostate cancer (30) 30
ctla-4 protein (29) 29
autoimmune hypophysitis (28) 28
autoimmunity (28) 28
drug therapy (28) 28
immune-related adverse events (28) 28
aged, 80 and over (27) 27
patients (27) 27
tumor-regression (27) 27
cell biology (26) 26
complications and side effects (26) 26
immune checkpoint blockade (26) 26
medical research (26) 26
mice, inbred c57bl (26) 26
programmed cell death 1 receptor - antagonists & inhibitors (26) 26
review (26) 26
apoptosis (25) 25
cells (25) 25
ctla-4 antigen (25) 25
hypophysitis (25) 25
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (482) 482
French (20) 20
German (6) 6
Polish (2) 2
Spanish (2) 2
Czech (1) 1
Japanese (1) 1
Korean (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
BULLETIN DU CANCER, ISSN 0007-4551, 01/2019, Volume 106, Issue 1, pp. 37 - 47
The offer of anti-cancer drugs has recently been disrupted by the introduction of checkpoint inhibitors on the market. Currently, one anti-CTLA-4, two... 
Anti-PD-1 | ONCOLOGY | Medicines | Anti-PD-L1 | Anti-CTLA-4 | CAR-T cells | Immunotherapies
Journal Article
Bulletin du Cancer, ISSN 0007-4551, 01/2019, Volume 106, Issue 1, pp. 37 - 47
The offer of anti-cancer drugs has recently been disrupted by the introduction of checkpoint inhibitors on the market. Currently, one anti-CTLA-4, two... 
Anti-PD-1 | Medicines | Anti-CTLA-4 | Anti-PD-L1 | CAR-T cells | Immunotherapies
Journal Article
Cancer, ISSN 0008-543X, 10/2016, Volume 122, Issue 19, pp. 3051 - 3058
Journal Article
by Arce Vargas, Frederick and Furness, Andrew J.S and Solomon, Isabelle and Joshi, Kroopa and Mekkaoui, Leila and Lesko, Marta H and Miranda Rota, Enrique and Dahan, Rony and Georgiou, Andrew and Sledzinska, Anna and Ben Aissa, Assma and Franz, Dafne and Werner Sunderland, Mariana and Wong, Yien Ning Sophia and Henry, Jake Y and O’Brien, Tim and Nicol, David and Challacombe, Ben and Beers, Stephen A and Spain, Lavinia and Wotherspoon, Andrew and Francis, Nicholas and Smith, Amy and Smith, Sean and Smith, Myles and Smith, Elaine and Strauss, Dirk and Hayes, Andrew and Soultati, Aspasia and Stares, Mark and Lynch, Joanna and Fotiadis, Nicos and Fernando, Archana and Hazell, Steve and Chandra, Ashish and Pickering, Lisa and Rudman, Sarah and Chowdhury, Simon and Swanton, Charles and Jamal-Hanjani, Mariam and Veeriah, Selvaraju and Shafi, Seema and Czyzewska-Khan, Justyna and Johnson, Benjamin and Johnson, Diana and Laycock, Joanne and Bosshard-Carter, Leticia and Goh, Gerald and Rosenthal, Rachel and Gorman, Pat and Murugaesu, Nirupa and Hynds, Robert E and Wilson, Gareth and Birkbak, Nicolai J and Watkins, Thomas B.K and McGranahan, Nicholas and Horswell, Stuart and Mitter, Richard and Escudero, Mickael and Stewart, Aengus and Van Loo, Peter and Rowan, Andrew and Xu, Hang and Turajlic, Samra and Hiley, Crispin and Abbosh, Christopher and Goldman, Jacki and Stone, Richard Kevin and Denner, Tamara and Matthews, Nik and Matthews, Sue and Elgar, Greg and Ward, Sophia and Biggs, Jennifer and Costa, Marta and Begum, Sharmin and Phillimore, Ben and Chambers, Tim and Nye, Emma and Graca, Sofia and Al Bakir, Maise and Hartley, John A and Lowe, Helen L and Herrero, Javier and Lawrence, David and Hayward, Martin and Panagiotopoulos, Nikolaos and Kolvekar, Shyam and Falzon, Mary and Borg, Elaine and Simeon, Celia and Hector, Gemma and Aranda, Marie and Novelli, Marco and Oukrif, Dahmane and Janes, Sam M and Thakrar, Ricky and Forster, Martin and Ahmad, Tanya and Lee, Siow Ming and ... and Melanoma TRACERx Consortium and Renal TRACERx Consortium and Lung TRACERx Consortium
Immunity, ISSN 1074-7613, 04/2017, Volume 46, Issue 4, pp. 577 - 586
CD25 is expressed at high levels on regulatory T (Treg) cells and was initially proposed as a target for cancer immunotherapy. However, anti-CD25 antibodies... 
regulatory T cells | tumor immunotherapy | anti-CD25 | Treg depletion | inhibitory Fc receptor | CD25 | tumor microenvironment | Fc gamma receptors | anti-PD-1 | EFFECTOR | RESPONSES | LYMPHOCYTE-ASSOCIATED ANTIGEN-4 | CANCER-PATIENTS | MELANOMA | MONOCLONAL-ANTIBODY | ANTI-CTLA-4 ANTIBODIES | IMMUNOLOGY | ANTITUMOR-ACTIVITY | COMBINATION | GAMMA-RS | T-Lymphocytes, Regulatory - metabolism | Immunotherapy - methods | Humans | Antibodies, Monoclonal - therapeutic use | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Lymphocyte Depletion | Receptors, IgG - metabolism | T-Lymphocytes, Regulatory - immunology | Neoplasms - therapy | Flow Cytometry | Immunoglobulin Fc Fragments - immunology | Antibodies, Monoclonal - immunology | Interleukin-2 Receptor alpha Subunit - immunology | Kaplan-Meier Estimate | Programmed Cell Death 1 Receptor - metabolism | Receptors, IgG - immunology | Protein Binding - immunology | Animals | Neoplasms - immunology | K562 Cells | Cell Line, Tumor | Mice | Antibodies, Monoclonal - metabolism | Programmed Cell Death 1 Receptor - immunology | Neoplasms - pathology | Viral antibodies | Cell death | Analysis | Immunotherapy | Antibodies | T cells | Cancer | Fc receptors | Beer | Immunoglobulins | Lymphatic system | Immune response | Cytokines | Melanoma | Light emitting diodes | Lymphocytes T | Anticancer properties | Depletion | Lymphocytes | Tumors | Immune system | Report
Journal Article
Cell, ISSN 0092-8674, 11/2019, Volume 179, Issue 5, pp. 1177 - 1190.e13
Immune checkpoint therapy (ICT) shows encouraging results in a subset of patients with metastatic castration-resistant prostate cancer (mCRPC) but still... 
bone metastases | castration-resistant prostate cancer | anti-CTLA-4 | TGF-β blockade | anti-PD-1 | Th1 subset | EFFECTOR | CELLS | TGF-BETA | MEMORY | IFN-GAMMA | BIOCHEMISTRY & MOLECULAR BIOLOGY | COMBINED NIVOLUMAB | DIFFERENTIATION | CANCER | TH17 | IPILIMUMAB | CELL BIOLOGY
Journal Article
Cancer, ISSN 0008-543X, 10/2016, Volume 122, Issue 19, pp. 3051 - 3058
Precis: For melanoma brain metastases, immune checkpoint therapy administered within 4 weeks of SRS is more effective than treatment separated by more than 4... 
melanoma | anti-CTLA-4 | anti-PD-1 | brain metastases | immunotherapy | stereotactic radiosurgery
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 05/2010, Volume 16, Issue 10, pp. 2861 - 2871
Journal Article
Journal Article
Revue des Maladies Respiratoires Actualites, ISSN 1877-1203, 10/2018, Volume 10, Issue 4, pp. 469 - 480
The development of immunotherapy with checkpoints inhibitors in non-small cell lung cancer has been conducted at an unprecedented scale, leading to a vast... 
Anti-PD-1 | Anti-CTLA-4 | Anti-PD-L1 | Immunotherapy | Lung cancer
Journal Article
Biochemical and Biophysical Research Communications, ISSN 0006-291X, 04/2019, Volume 512, Issue 2, pp. 244 - 249
Comprehensive knowledge on the murine CT26 colon carcinoma line is a classic model used in the pharmacodynamic experiments involving IDO-1 inhibitors,... 
Anti-PD-1antibody | Anti-CTLA-4 antibody | Tumor microenvironment | Murine colon carcinoma | Treg | Cytotoxic T cells | GAMMA | CELLS | APOPTOSIS | BIOCHEMISTRY & MOLECULAR BIOLOGY | BIOPHYSICS | INHIBITORS | EXPRESSION | PD-1 | T-LYMPHOCYTES | Viral antibodies | Antibodies | Colon cancer | T cells | Analysis | Cancer
Journal Article
Journal of Experimental Medicine, ISSN 0022-1007, 10/2013, Volume 210, Issue 11, pp. 2435 - 2466
Journal Article